SARCLISA® (isatuximab-irfc) | Official Patient Website
Info for patients about the efficacy and safety of SARCLISA (a therapy for multiple myeloma) and how SARCLISA works. See Important Safety & Prescribing Info.
SARCLISA® (isatuximab-irfc) | Newly Diagnosed Trial Results
What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
SARCLISA® (isatuximab-irfc) | Patient and Caregiver Resources
What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
SARCLISA® (isatuximab-irfc) | How SARCLISA Is Given
What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
SARCLISA® (isatuximab-irfc) | About Multiple Myeloma
What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
SARCLISA® (isatuximab-irfc) | Get Updates About SARCLISA - get …
What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
SARCLISA® (isatuximab-irfc) | Previously Treated Trial Results
What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- [PDF]
NOW FDA APPROVED
• SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein. • SARCLISA is given in treatment cycles of 28 days (4 weeks), together with either the medicines pomalidomide and dexamethasone, or carfilzomib and dexamethasone. – shortness of breath, wheezing, or trouble breathing
SARCLISA is a prescription medicine used in combination with: • The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
SARCLISA® (isatuximab-irfc) | A Targeted Immunotherapy
SARCLISA is a targeted immunotherapy used in combination with other medicines to treat multiple myeloma.